MG冰球突破官网

Founded in 2012, Jiangsu Recbio Technology Co., Ltd. (stock code: 02179.HK) is an innovative vaccine company propelled by internally developed technologies. Committed to our mission of " Protect human health with best-in-class vaccines", we have developed a comprehensive vaccine innovation engine consisting of a novel adjuvant platform, protein engineering platform and immunological evaluation platform. We are one of the few companies that are capable of independently developing and commercializing a full range of novel adjuvants. Our vaccine portfolio currently consists of more than 10 high-value innovative vaccine pipelines, covering HPV, shingles, RSV and other major diseases. Our core products recombinant HPV 9-valent vaccine REC603 and novel adjuvanted recombinant shingles vaccine REC 610, are under phase III clinical trial.